What Happened: GSK announced an agreement to acquire 35Pharma, a Canada-based clinical-stage biopharmaceutical company, for $950 million in cash. The acquisition centers on HS235, an investigational medicine that has completed Phase 1 trials, with Phase 2 studies starting imminently in PAH and PH-HFpEF.

Why It Matters: HS235 targets the activin receptor signaling pathway, a clinically validated target in PAH. Crucially, it is designed with enhanced selectivity, reducing binding to BMP9 and BMP10—ligands associated with bleeding and telangiectasia adverse events. By potentially lowering bleeding risk, HS235 addresses a key limitation of current treatments.

Executive Impact: The pulmonary hypertension market is forecast to reach $18 billion by 2032. GSK gains a potential best-in-class asset to compete directly with Merck's Winrevair, which reached $1.4 billion in 2024 sales.

What Happened: The FDA issued landmark draft guidance establishing a dedicated regulatory pathway for individualized therapies (antisense oligonucleotides and gene editing). (Feb 23)

The Policy: The "Plausible Mechanism Framework" allows for full approval based on "substantial evidence" from non-traditional, small-scale trials when randomized controlled trials are biologically or ethically unfeasible.

Why It Matters: This codifies the "Makary-Kennedy" pivot toward regulatory flexibility. By aligning regulation with modern biology (RNA/CRISPR), the FDA is effectively lowering the capital barrier for "bespoke" medicine.

Executive Impact: Sponsors can now leverage confirmatory evidence (biomarkers and mechanistic data) to bypass multi-year Phase 3 requirements for ultra-rare mutations, provided they address the root genetic cause.

Approval: The FDA converted the accelerated approval for Braftovi (encorafenib) into full traditional approval for first-line BRAF V600E+ metastatic colorectal cancer.

Data: The BREAKWATER trial showed a 51% reduction in death risk (median OS 30.3 vs 15.1 months) and 61% vs 40% ORR.

Data: Reported a robust 72.2% ORR for onvansertib plus FOLFIRI/bev in 1L RAS-mutated mCRC—a significant jump over the 43.2% seen with standard of care. Hazard ratio was 0.37 (p<0.05) for progression-free survival.

Filing: The FDA accepted the BLA for imsidolimab in generalized pustular psoriasis (GPP), setting a PDUFA date of December 12, 2026. This sets up Vanda for its third approval in a 12-month cycle.

Data: Published Phase 2b results in Cell Stem Cell showing that laromestrocel (MSC therapy) improved 6-minute walk distance by 63.4 meters at nine months (p=0.0077) in patients with clinical frailty. TIE-2 was identified as a potential biomarker for responsiveness.

Partnership: Inked a massive deal with Vivtex to develop next-gen oral formulations for peptides and proteins. Vivtex's GI-ORIS screening platform uses "gut on a chip" technology to enable oral delivery of biologics traditionally limited to injection.

Confirmation: Confirmed its KLRG1 antibody flunked all primary goals in a Phase 2/3 muscle disease trial, effectively ending the program's development for inclusion body myositis.

Licensing: Licensed two siRNA kidney disease assets from Frontier Biotechnologies for $40M upfront and up to $963M in milestones. This continues GSK's aggressive move into oligonucleotide therapeutics targeting inflammation-driven renal conditions.

Divestiture: Announced the sale of its CDMO and Cell Solutions businesses to GI Partners, and European discovery assets to IQVIA, for ~$145M.

Impact: The moves reduce 2026 revenue by ~$200M but add ~100bps to operating margin and ~$0.10 to non-GAAP EPS.

M&A: Quantum acquired J&J's NeuWave Medical microwave ablation system. It will be integrated into Quantum's Epione robotic platform under new parent company Precision IO Group.

Legal: A coalition of 15 states filed suit challenging HHS Secretary Kennedy's replacement of the ACIP committee, seeking to invalidate January's childhood immunization schedule changes. The lawsuit alleges Kennedy unlawfully fired existing members and appointed replacements lacking scientific qualifications.

Regulation: New Zealand is implementing its new 30-day verification pathway for drugs approved by two trusted regulators (FDA, EMA, TGA, etc.) to drastically shorten domestic launch timelines.

Safety: The FDA issued a safety warning regarding Impella heart pump Generation 1 Purge Cassettes after four injuries related to cassette leaks. The agency urges transition to Generation 2 components.